$9.47
0.00% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Theravance Biopharma Inc Stock price

$9.47
+0.92 10.76% 1M
+1.13 13.55% 6M
-1.77 15.75% YTD
-1.03 9.81% 1Y
+1.02 12.07% 3Y
-9.03 48.81% 5Y
-6.12 39.26% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Key metrics

Market capitalization $465.68m
Enterprise Value $419.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.64
P/S ratio (TTM) P/S ratio 7.37
P/B ratio (TTM) P/B ratio 2.51
Revenue growth (TTM) Revenue growth 15.93%
Revenue (TTM) Revenue $63.19m
EBIT (operating result TTM) EBIT $-39.48m
Free Cash Flow (TTM) Free Cash Flow $-12.31m
Cash position $91.36m
EPS (TTM) EPS $-1.01
P/E forward negative
P/S forward 7.44
EV/Sales forward 6.70
Short interest 19.64%
Show more

Is Theravance Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Theravance Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Theravance Biopharma Inc forecast:

2x Buy
40%
3x Hold
60%

Analyst Opinions

5 Analysts have issued a Theravance Biopharma Inc forecast:

Buy
40%
Hold
60%

Financial data from Theravance Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
63 63
16% 16%
100%
- Direct Costs 6.37 6.37
14% 14%
10%
57 57
16% 16%
90%
- Selling and Administrative Expenses 55 55
11% 11%
87%
- Research and Development Expense 35 35
24% 24%
55%
-33 -33
44% 44%
-52%
- Depreciation and Amortization 6.37 6.37
14% 14%
10%
EBIT (Operating Income) EBIT -39 -39
39% 39%
-62%
Net Profit -49 -49
13% 13%
-78%

In millions USD.

Don't miss a Thing! We will send you all news about Theravance Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Theravance Biopharma Inc Stock News

Neutral
PRNewsWire
6 days ago
DUBLIN , Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment community at the conference.  Webcast of the event may be accessed by visiting Theravance.com, under the In...
Neutral
Seeking Alpha
13 days ago
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Aine Miller - Head, Development Conference Call Participants Julian Harrison - BTIG Ernie Rodriguez - TD Cowen Douglas Tsao - H.C. Wainwright Operator Lad...
Neutral
PRNewsWire
14 days ago
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241 CYPRESS enrollment in-line with expectations, with timelines on track TRELEGY net sales increased 17%, to $789 million, as reported by GSK: Q4 sales of at least ~$2...
More Theravance Biopharma Inc News

Company Profile

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Head office Cayman Islands
CEO Rick Winningham
Employees 99
Founded 2013
Website www.theravance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today